RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
RenovoRx announced that CEO Shaun Bagai and CFO Mark Voll will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026 in New York. Management plans to review third quarter 2026 financial and business results and discuss commercial growth of the TAMP platform, which has previously generated $1.1 million in 2025 RenovoCath sales and a record $909,000 in Q2 2026 revenue.
Key figures
- Q2 2026 revenue
- 909000
- Topline data expected
- second half of 2027
- Trial completion expected
- first half of 2027
- Trial enrollment completed
- August 2026
- First year renovocath sales 2025
- $1.1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.